LivaNova (LIVN) Could Be 12% Undervalued Following Recent Share Price Cooling
LivaNova (LIVN) last closed at US$78.18, leaving investors weighing recent share moves against the company’s profile as a medical technology player across cardiopulmonary systems and neuromodulation therapies.
Recent trading has cooled slightly, with a 1-day share price return of 0.95% and a 7-day move down 3.72%. However, the year-to-date share price return of 28.92% and 1-year total shareholder return of 36.34% point to momentum that has been building rather than fading.
Scan how LivaNova fits among other medical and health-focused players by comparing it with a hand-picked list of solid balance sheet and fundamentals (23 results).
LivaNova now trades meaningfully below both analyst targets and an estimated fair value range, after a strong run. Is the recent cooling a reset, or a sign the valuation still has room to compress further?
Most Popular Narrative: 12.3% Undervalued
LivaNova's most followed valuation story pins fair value at $89.10 per share, which sits above the latest close at $78.18 and frames the recent pullback in a different light.
The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.
Want the full story behind that premium on LivaNova. The fair value call leans heavily on compounding revenue, firmer margins, and a richer future earnings multiple.
The most widely followed narrative builds this $89.10 estimate using an 8.06% discount rate, a mid single digit lift in profit margin assumptions, and revenue growth expectations that run ahead of current reported trends. Those inputs work together to support a higher implied P/E on future earnings than what the share price currently reflects, even though the future multiple in the model still sits below the broader medical equipment peer group.
Result: Fair Value of $89.10 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the LivaNova narrative can crack if reimbursement tightens or if higher R&D spending fails to translate into commercially successful neuromodulation or OSA products.
Find out about the key risks to this LivaNova narrative.
Next Steps
Mixed signals around LivaNova's valuation and clinical progress can feel murky, so move quickly to review the underlying data, stress test the bullish and cautious arguments, and then weigh the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond LivaNova?
If LivaNova has your attention, widening your watchlist with a few focused screeners can help you spot opportunities you might otherwise miss.
- Target potential mispricings by scanning a curated 33 high quality undervalued stocks that filters for quality businesses trading below their estimated worth.
- Strengthen your downside protection by reviewing a 11 resilient stocks with low risk scores designed to highlight companies with more resilient profiles.
- Get ahead of the crowd by checking a 18 high quality undiscovered gems that surfaces under-the-radar stocks with solid fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com